GATA-1 protein is thought to be a positive regulator of erythroid differentiation. However, ectopic expression of a conditional GATA-Z/estrogen receptor chimera was shown to inhibit erythroid differentiation in a hormone-dependent manner, suggesting the negative regulation of erythroid differentiation by GATA-2 protein. Accordingly, we reasoned that the quantitative balance of GATA-1 and GATA-2 protein might affect erythroid differentiation. In this report, we performed specific and quantitative measurements of GATA-1 HE GATA FACTORS are a family of (C,) zinc finger transcriptional regulatory proteins in eukaryocytes that bind to the consensus DNA sequence WGATAR.' In vertebrate organisms, each member of this family has a distinct tissue distribution pattern. GATA-1 is expressed in the erythroid, megakaryocytic, and mast cell whereas GATA-2 is expressed more widely in both hematopoietic and nonhematopoietic lineage^.^,^ GATA-3 is highly expressed in T cells and embryonic brain cells,738 but elsewhere, it is expressed at a low level. Expression of GATA-4 is restricted to the heart, intestinal epithelium, primitive endoderm, and gonads. ' A curious aspect of GATA expression is that in several developmentally distinct lineages (eg, in erythroid and megakaryocytic cells), multiple members of the GATA gene family are coexpre~sed.'~~~ However, little is known how differential gene regulation is accomplished in cells expressing more than one GATA gene. One possibility is that differential regulation is controlled by selective high-affinity binding of one, but not other, GATA family members to a target sequence as a consequence of subtle variations in their DNAbinding domains. In fact, Merika et all' have shown that the precise DNA-binding preferences of GATA-1 and GATA-3 are different. By contrast, the DNA-binding specificities of GATA-1 and GATA-2 are quite similar. In this context, it is difficult to explain coexpression of GATA-1 and GATA-2 mRNA in erythroid cells. Another possibility is that the precise quantitative balance of the GATA factors controls differential regulation. However, examination of this balance has not been performed because specific and quantitative measurement of GATA proteins is extremely difficult. In this report, we have performed specific and quantitative protein assays for GATA-1 and GATA-2. On the basis of these assays, we show that 12-0-tetradecanoylphorbol 13-acetate (TPA) treatment triggers both downregulation of GATA-1 protein and upregulation of GATA-2 protein during the TPA-induced arrest of erythroid differentiation in a new erythroid cell line SAM-1. erythropoietin receptor antibodies'* were generous gifts from Genetics Institute (Cambridge, MA). Monoclonal antiglycophorin A and antiplatelet glycoprotein IIb antibodies were obtained from AMAC, Inc (Westbrook, ME). A hybridoma producing anti-HLA class I monoclonal antibody (clone W6/32) was obtained from American Type Culture Collection (Rockville, MD). GATA-I and GATA-2 cDNA probes''.l4 were generously provided by Dr Stuart Orkin (Children's Hospital, Boston, MA). Glycophorin A and y globin cDNA probe^'^,'^ were kindly provided by Dr Wei Dai (Hipple Cancer Research Center, Dayton, OH) and Dr Bernard G. Forget (Yale University, New Haven, CT), respectively. Platelet glycoprotein Iba, platelet glycoprotein IIb, and platelet factor 4 cDNA were generous gifts from Otsuka America Pharmaceutical, Inc (Rockville, MD). Oligonucleotide probes and competitors for the electrophoretic mobility shift assay were purchased from Oligo Etc, Inc (Wilsonville, OR).
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T MATERIALS AND METHODS

Materials
Cell culture. SAM-l cells were grown in suspension culture in RPM1 1640 medium containing 10% fetal calf serum (GIBCO BRL, Gaithersburg, MD), 100 uglmL penicillin, 50 ug/mL streptomycin. For treatment with TPA, exponentially growing SAM-l cells were collected and resuspended in fresh culture medium containing TPA (1 or 5 nglmL) and cultured for up to 2 days. As TPA stock solution (1 mg/mL) was prepared in dimethyl sulfoxide (DMSO), SAM-l cells incubated with DMSO alone were also examined as a negative control for TPA treatment.
Immunojluorescence. Cell-surface antigens were detected by immunofluorescence staining. Briefly, SAM-l cells were incubated for 30 minutes at 4°C with the appropriately diluted monoclonal antibodies. As a negative control, SAM-l cells were also incubated with the appropriately diluted mouse IgG. After washing, the cells were reincubated with fluorescein-labeled F(ab' ), fragments of goat anti- Immunoblotting. Relative levels of GATA-I protein were assessed by immunoblot analysis as previously described.*' The rat monoclonal antibody specific to GATA-I protein was detected with horseradish peroxidase-conjugated goat antirat Ig antibody using enhanced chemiluminescence detection reagents (Amersham International, Buckinghamshire, England).
Electrophoretic gel mobility sh$Iwper.sh(ft assay. Electrophoretic gel mobility shift assay (EGMSA) was performed essentially as described by Nagai et al" with minor modifications. Briefly, an oligonucleotide containing a GATA binding consensus sequence found in the mouse 01-globin promoter (Map) was used for the DNA-binding assay. The binding buffer consisted of 20 mmol/L HEPES (pH 7.
.2 mmol/L P-mercaptoethanol, 0.01% Nonidet P-40, and 10% glycerol. We added 3 pg of Poly(d1-dC) to a reaction mixture as an inhibitor of nonspecific protein-DNA binding. A 100-or 200-fold excess of unlabeled MaP was used as sequence-specific competitors, whereas two oligonucleotides of similar size, lacking the W/GATA/ R motif, were employed as nonspecific competitors. Nuclear minilysate was prepared from I X IO7 SAM-l cells as previously de~cribed.'~ Binding reaction (10 pL) was performed for 30 minutes on ice with IO pg of the nuclear lysate. In the supershift experiments, 1 p L of rat anti-GATA-I polyclonal antibodies" or 3 pL of rat anti-GATA-I monoclonal antibodies (Santa CNZ Biotechnology, Santa Cruz, CA) were added to the reaction mixtures after the 10-minute incubation period, and the mixtures were incubated for an additional 20 minutes. Mouse anti-GATA-2 antibodies'j were first mixed with the lysate and incubated for IO minutes, and the probe was then added to the mixture. The reaction mixtures were electrophoresed on 4% nondenaturing polyacrylamide gels in low ionic strength buffer (8 mmol/L Tris HCI, pH 7.5; 3.3 mmol/L sodium acetate; 1 mmol/L EDTA) at room temperature.
RESULTS
Establishment of the SAM-I cell line. The SAM-l cell line is a new erythroid-megakaryocytic cell line established from a patient in blast crisis of chronic myelogenous leukemia. SAM-l and parental cells shared Ph, chromosomes and showed the identical bcr rearrangement pattern in Southern blot analysis (data not shown). Phenotypic characteristics of SAM-l cells were also similar to parental cells, indicating the derivation of SAM-l cells from parental cells. Briefly, SAM-l cells were positive for glycophorin A, platelet glycoprotein Ib, platelet glycoprotein Ilb, platelet glycoprotein IIb/ Illa, and platelet peroxidase but negative for B-cell antigens (CD19 and CD20), T-cell antigens (CD2, CD3, CD4, CD5, and CD8). NK-cell antigens (CD57), or myeloid antigens (CD1 Ib and CD13). SAM-l cells also expressed y-globin mRNA. However, erythropoietin receptors were undetectable by immunofluorescence using monoclonal antierythropoietin antibodies.
Phenotypic changes of SAM-I cells a f e r treatment with TPA. It has been shown that glycophorin A andlor y-globin gene expression is negatively regulated in K562 or HEL Effect of TPA on platelet glycoprotein Ilb, GATA-1, and GATA-2 mRNA levels in SAM-l cells. RNA was extracted from SAM-1 cells after treatment with 5 ng/mL TPA for 12 hours. RNA extracted from a megakaryoblastic cell line (CMK) was used as a positive control for platelet glycoprotein Ilb. Blots were hybridized with "P-labeled cDNA probes specific for platelet glycoprotein Ilb. RNA blots were subsequently rehybridized with "P-labeled GATA-1 or GATA-2 cDNA probes. Further rehybridization with '2P-labeled human ribosomal DNA probes was performed t o control for amounts of RNA per lane (283.
3, TPA downregulated glycophorin A antigens confirming previous reports.".'" However, Dai et observed no significant changes in glycophorin A protein levels after TPA treatment, while they also reported dramatic reduction of glycophorin A mRNA expression after TPA stimulation. Although the reason is currently unknown, this may be due to the difference in the cells (SAM-l cells IT HEL cells) or assays (flow cytometry I' immunoblotting) employed in the experiments.
Consistent with the results of RNA blotting analysis, TPA did not induce the expression of megakaryocytic antigens such as platelet glycoprotein Ib or Ilb in contrast to K562 or HEL cell^'^^'' (Fig 3 and data not shown) . Therefore.
TPA does not provoke differentiation of SAM-l cells into megakaryocytic lineage. These results suggest that the erythrocyte to megakaryocyte lineage switch triggered by TPA actually consists of two processes (ie, arrest of erythroid differentiation and induction of megakaryocytic differentiation). The availability of SAM-l cells that respond to TPA differently from K562 or HEL cells would be helpful for further analysis of these processes.
Finally, no myeloid antigens (CD13 or CD33 antigens) were induced on SAM-1 cells after TPA treatment (data not shown). Thus, in summary, SAM-l cells expressed none of these erythroid, megakaryocytic, and myeloid antigens after TPA treatment. However, the loss of these antigens is not a nonspecific effect because HLA class I antigens were upregulated (Fig 3) .
TPA downregulates GATA-l expression and upregulates GATA-2 expression.
Recent studies'"." have shown that GATA-I is an essential transcriptional activating factor in erythroid differentiation. In this context, several investigahave reported that downregulation of GATA-I mRNA and DNA-binding activity is coupled with reduced expression of several erythroid genes including glycophorin A gene. However, it is unclear whether this DNA-binding activity represents GATA-I protein for the following reasons: ( l ) The cell lines used in these studies express both GATA-I and GATA-2 mRNA. (2) EGMSA employed in these studies might detect any members of GATA DNAbinding protein family, as probes contained the GATA consensus motif. Thus, we performed immunoblot analysis using a monoclonal antibody specific for GATA-I protein. As shown in Figs 1 and 4 , TPA downregulated GATA-1 protein, as well as GATA-I mRNA, confirming the previous reTo examine the expression of GATA-I protein, we also performed EGMSA and observed a band in the cell extract before TPA treatment (band F in Fig 5A) . When the anti-GATA-I serum or anti-GATA-I monoclonal antibody was added to an EGMSA reaction, we detected the supershift of the band F in the lysate prepared from untreated SAM-l cells (Fig 5B) . This observation indicates that the band F mainly consists of a complex of GATA-I and MaP probe. TPA decreased the intensity of band F, consistent with the result of immunoblotting (Fig 5A) .
Recently, Briegel et alM reported that GATA-2 might inhibit erythroid differentiation of erythroid progenitor cells. Therefore, we asked whether TPA upregulates GATA-2 mRNA and protein during TPA-induced arrest of erythroid differentiation. As shown in Fig I , TPA increased expression of GATA-2 mRNA in SAM-l cells. However, it was difficult to measure GATA-2 protein quantitatively as currently available anti-GATA-2 antibodies were not applicable to immunoblot analysis. Thus, we measured GATA-2 protein specifically and quantitatively by EGMSA using anti-GATA-2 monoclonal antibodies. We detected a band in the lysate prepared from SAM-l cells after TPA treatment (band S in Fig 5A) . As shown in Fig SC, formation of this DNA/ protein complex was inhibited by specific competitors, but po**2s.'2.~' unaffected by nonspecific competitors lacking the W/GATA/ R motif. Therefore, the protein yielding the band S is one of the GATA DNA-binding protein family. Moreover, pretreatment of the SAM-l lysate with the GATA-2-specific antibody suppressed the formation of this DNNprotein complex, thereby demonstrating that this complex contains GATA-2 (Fig 5'2) . The antibody did not form a supershift complex. Thus, these results suggest that TPA treatment upregulates GATA-2 protein, as well as GATA-2 mRNA in SAM-1 cells.
GATA-3 mRNA was undetectable in SAM-l cells, as in other human erythroleukemia cell lines" (data not shown). TPA did not induce GATA-3 mRNA in SAM-l cells (data not shown). GATA-3 protein is probably not expressed in SAM-l cells because EGMSA showed no band other than the band F and S (data not shown). Thus, GATA-3 is presumably not involved in the negative regulation of erythroid differentiation.
DISCUSSION
There are detailed studies about the patterns of expression of GATA-1 and GATA-2 mRNA during erythroid develop-
However, little is known about the behavior of GATA-1 and GATA-2 protein during erythroid differentiation. Although there are a few studies's~'2~'' regarding the behavior of GATA-1 protein during erythroid differentiation, it is not clear whether GATA-l protein is accurately measured in these studies for the following reasons: ( l ) These studies were performed in cells expressing both GATA-I and GATA-2 mRNA. (2) The electrophoretic mobility shift assay employed in these studies might detect both GATA-I and GATA-2 protein, as probes contained consensus GATA motif sequences. Therefore, we performed protein blotting using a monoclonal antibody specific for GATA-I protein.
We observed downregulation of GATA-I protein in SAM-1 cells after treatment with TPA, confirming previous reTo our knowledge, there are no reports on the dynamics of GATA-2 protein expression in erythroid differentiation. In this study, we quantified GATA-2 protein by EGMSA using anti-GATA-2 antibodies. On the basis of EGMSA, we have shown upregulation of GATA-2 protein in SAM-l cells after treatment with TPA. Therefore, TPA-induced arrest of erythroid differentiation involves both downregulation of GATA-I protein and upregulation of GATA-2 protein, suggesting the importance of precise quantitative balance of GATA-I and GATA-2 protein in the control of erythroid differentiation. Consistent with this idea, Leonard et al" described that differentiation of normal cells toward mature erythroid cells is coupled with upregulation of GATA-I mRNA and downregulation of GATA-2 mRNA. However, it will be important to confirm these results by measuring GATA-I and GATA-2 proteins in their system.
Previously, a loss of expression of several erythroid genes by TPA treatment was attributed to downregulation of GATA-l because GATA-I was the only well-characterized transcriptional factor in the erythroid GATA-1 binds to GATA-motif sequences within promoters a n d or enhancers of essential erythroid genes and works as a the functions of GATA-l and GATA-2. A question for further study is the extent to which the quantitative balance of GATA-I and GATA-2 protein influences the expression of potential target genes in vivo.
The role of GATA-I and GATA-2 during megakaryocytic differentiation is less clear compared with that of GATA-1 and GATA-2 during erythroid differentiation. Recently, Visvader et a14".4' demonstrated that stable expression of GATA-I or GATA-2 transgene induces megakaryocytic differentiation of the primitive myeloid cell line 416B and suggested the significance of these GATA transcriptional factors In fact, y interferon and tumor necrosis factor a are known to suppress the formation of colony-forming units-erythroid (CFU-E) and burst-forming units-erythroid (BFU-E).# This possibility is now under investigation.
